TLSA
Tiziana Life Sciences Ltd
$
1.740
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.770
Open
1.590
VWAP
1.69
Vol
328.63K
Mkt Cap
206.75M
Low
1.530
Amount
556.54K
EV/EBITDA(TTM)
--
Total Shares
101.51M
EV
199.61M
EV/OCF(TTM)
--
P/S(TTM)
--
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Show More
Valuation Metrics
The current forward P/E ratio for Tiziana Life Sciences Ltd (TLSA.O) is -9.41, compared to its 5-year average forward P/E of -5.51. For a more detailed relative valuation and DCF analysis to assess Tiziana Life Sciences Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.51
Current PE
-9.41
Overvalued PE
-2.85
Undervalued PE
-8.18
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TLSA News & Events
Events Timeline
2025-09-25 (ET)
2025-09-25
08:33:48
Tiziana Life Sciences to progress development of TZLS-501 monoclonal antibody
2025-09-15 (ET)
2025-09-15
08:04:10
Tiziana Life Sciences Receives Research Grant from U.S. Department of Defense for SCI Study
2025-08-14 (ET)
2025-08-14
08:35:28
Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab
Sign Up For More Events
Sign Up For More Events
News
4.5
11-11BenzingaElon Musk Indicates Tesla and xAI Are Moving Towards Convergence in Certain Aspects
9.0
09-25NewsfilterTiziana to Progress with TZLS-501, Its Fully Human Monoclonal Antibody Targeting IL-6R
1.0
09-24NewsfilterTiziana Life Sciences to Present Poster on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
Sign Up For More News
People Also Watch
FAQ
What is Tiziana Life Sciences Ltd (TLSA) stock price today?
The current price of TLSA is 1.74 USD — it has increased 7.74 % in the last trading day.
What is Tiziana Life Sciences Ltd (TLSA)'s business?
What is the price predicton of TLSA Stock?
What is Tiziana Life Sciences Ltd (TLSA)'s revenue for the last quarter?
What is Tiziana Life Sciences Ltd (TLSA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tiziana Life Sciences Ltd (TLSA)'s fundamentals?
How many employees does Tiziana Life Sciences Ltd (TLSA). have?